Divi's Laboratories Elevates Two Senior Procurement Leaders to Top Management
The Indian pharmaceutical ingredients manufacturer appointed two general managers with over 30 years of experience each to its senior management team.
Procurement Veterans Join Senior Leadership
Divi's Laboratories Limited, India's $22 billion pharmaceutical ingredients manufacturer, has appointed two long-tenured procurement specialists to its senior management team, effective August 1, 2026, according to a regulatory filing with India's stock exchanges.
The Board of Directors approved the elevation of Mr. B. Vara Prasad, General Manager (Engineering Purchase), and Mr. J. Srinivasa Rao, General Manager (Raw Materials Purchase), to Senior Management Personnel positions during its meeting on August 1, 2026 (FIN SUPP filing, 2026-08-01).
Decades of Industry Experience
Both appointees bring extensive pharmaceutical industry expertise to their expanded roles. Mr. Vara Prasad holds a master's degree in business administration and joined Divi's Laboratories in 1994, accumulating over 31 years of experience in the pharmaceutical sector (FIN SUPP filing, 2026-08-01). He is described as "a highly accomplished Supply Chain and Procurement professional" who has "played a pivotal role in managing the procurement of high-value capital equipment and in coordinating the development and commissioning of new manufacturing facilities" (FIN SUPP filing, 2026-08-01).
Mr. Srinivasa Rao, also holding an MBA, joined the company in 1995 and brings over 30 years of pharmaceutical industry experience (FIN SUPP filing, 2026-08-01). According to the filing, he "is a highly skilled professional with over 30 years of experience in managing and optimizing procurement operations in the pharmaceutical industry" with expertise in "strategic sourcing, vendor development, contract negotiation, regulatory compliance and cross-functional coordination" (FIN SUPP filing, 2026-08-01).
Strategic Procurement Responsibilities
In his elevated role, Mr. Vara Prasad will continue to oversee all engineering-related procurement for the company. The filing notes he "brings deep domain expertise in management, contract negotiations, and large-scale project execution" with particular strength in "energy-efficient energy systems" (FIN SUPP filing, 2026-08-01).
Mr. Srinivasa Rao will maintain responsibility for "end-to-end raw materials procurement in the Company" (FIN SUPP filing, 2026-08-01). The filing highlights his contributions to the "implementation of diversified and sustainable supply chain" practices (FIN SUPP filing, 2026-08-01).
Governance Context
The appointments were recommended by the company's Nomination and Remuneration Committee before receiving Board approval. The filing disclosed that neither appointee has any relationship with the company's directors (FIN SUPP filing, 2026-08-01).
The promotions coincided with the Board's approval of unaudited financial results for the quarter ended June 30, 2026, and came ahead of the company's Annual General Meeting scheduled for August 10, 2026, according to MarginX data.
Divi's Laboratories, headquartered in Hyderabad, manufactures active pharmaceutical ingredients, intermediates, and nutraceutical ingredients. The company's stock closed at ₹8,056 prior to the announcement.
This article was generated by MarginX from the FIN SUPP filing on 2026-08-01. It is not investment advice.